Manufacturer
Janssen
Contents
Guselkumab
Indication
Plaque psoriasis.
Instruction
Administer via Subcutaneous: In patients with moderate to severe cases who are candidates for systemic therapy or phototherapy: Initially, 100 mg at weeks 0 and 4, then every 8 weeks thereafter. Discontinue therapy if no response after 16 weeks.
Drug interaction
Enhanced immunosuppressive effects with belimumab, infliximab.Potentially Fatal: May enhance adverse/toxic effects of live vaccines.
Malaysia
